Sidley represented ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing next-generation RNA therapeutics, in its successful close of an oversubscribed US$200 million Series C financing led by Bain Capital and TCGX. The proceeds from the Series C financing will be used to further advance ADARx’s clinical programs, including drug candidates for the treatment of multiple complement-mediated diseases and hereditary angioedema, and to support advancement of a pipeline of innovative mRNA silencing or editing candidates. The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A), and included Jake Funk and Derek W. Kang (M&A).~~Sidley represented ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing next-generation RNA therapeutics, in its successful close of an oversubscribed US$200 million Series C financing led by Bain Capital and TCGX. The proceeds from the Series C financing will be used to further advance ADARx’s clinical programs, including drug candidates for the treatment of multiple complement-mediated diseases and hereditary angioedema, and to support advancement of a pipeline of innovative mRNA silencing or editing candidates. The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A), and included Jake Funk and Derek W. Kang (M&A).